MTIM
PRAX icon

Marathon Trading Investment Management’s Praxis Precision Medicines PRAX Stock Holding History

Marathon Trading Investment Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,000
Closed -$549K – 373
2024
Q1 		$549K Buy
+9,000
New +$404K 0.04% 147

Other funds holding PRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
VR Adviser
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Marathon Trading Investment Management's PRAX Position: Q2 2024 in Review

Marathon Trading Investment Management sold out of Praxis Precision Medicines (PRAX) in Q2 2024, closing a stake of 9,000 shares — an estimated $549K sold.

Marathon Trading Investment Management first reported a position in PRAX in Q1 2024 and held it in 1 quarter. The position peaked at $549K in Q1 2024. 113 funds tracked by Wall St. Rank hold PRAX as of Q2 2024.

  • Marathon Trading Investment Management reported no remaining Praxis Precision Medicines position as of Q2 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 9,000 Praxis Precision Medicines shares in Q2 2024, an estimated $549K.
  • Marathon Trading Investment Management first reported a position in Praxis Precision Medicines in Q1 2024 and held it in 1 quarter.
  • Marathon Trading Investment Management's Praxis Precision Medicines position peaked at $549K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2024.

Based on Marathon Trading Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.